Inositol

Base Information

• Chemical Name: Inositol
• CAS No.: 643-12-9
• Deprecated CAS: 53319-35-0,887751-76-0,36190-90-6,19030-27-4,173524-45-3
• Molecular Formula: C₆H₁₂O₆
• Molecular Weight: 180.158
• Hs Code.: 29061390
• European Community (EC) Number: 201-781-2,211-394-0,230-024-9,207-682-0,207-681-5,209-000-7,211-393-5,610-437-4
• NSC Number: 757076,404118,127230,103959,55558,55552,55551,45517,25142,8101
• UNII: 8LQ63P85IC,63GQX5QW03,9O6Y5O4P9W,M94176HJ2F,R1Y9F3N15A,6R79WV4R10,1VS4X81277,4L6452S749,4661D3JP8D,587A93P465
• DSSTox Substance ID: DTXSID7023146,DTXSID30110000,DTXSID101028818,DTXSID101028820,DTXSID201028823,DTXSID301028826,DTXSID50905091,DTXSID601028825,DTXSID901028824
• Nikkaji Number: J4.282J,J522.945F,J9.771C,J92.778C,J101.888D,J101.889B,J101.890F,J101.891D,J101.892B
• Wikipedia: Inositol,Allo-Inositol,1D-chiro-Inositol,Scyllo-Inositol,Neo-Inositol,Muco-Inositol,1L-chiro-Inositol,Epi-Inositol,Cis-Inositol
• Wikidata: Q407997,Q2838375,Q3011024,Q743661,Q3023527,Q3205874,Q3347078,Q3331426,Q3589114,Q2974313
• NCI Thesaurus Code: C122987,C28163,C189814
• RXCUI: 5833
• Metabolomics Workbench ID: 49811
• ChEMBL ID: CHEMBL468154,CHEMBL1950780,CHEMBL1231671,CHEMBL1222251,CHEMBL278373,CHEMBL3976780
• Mol file: 643-12-9.mol

Synonyms:inositol;myo-inositol;Scyllo-inositol;epi-Inositol;Muco-Inositol;Allo-inositol;i-Inositol;87-89-8;meso-Inositol;Neo-inositol;1D-Chiro-inositol;1L-Chiro-inositol;D-(+)-chiro-Inositol;cis-Inositol;643-12-9;488-59-5;D-chiro-Inositol;Myoinositol;Scyllitol;6917-35-7;Cyclohexane-1,2,3,4,5,6-hexaol;488-58-4;cyclohexane-1,2,3,4,5,6-hexol;Quercinitol;mesoinositol;Cocositol;551-72-4;Meat sugar;Myoinosite;Dambose;chiro-inositol;Inositene;Inositina;L-chiro-Inositol;Phaseomannite;Inosital;Inosite;Iso-inositol;Cyclohexitol;Phaseomannitol;41546-34-3;Inositol, myo-;Mesoinosit;Mesoinosite;Scyllite;Mesovit;Nucite;Mesol;643-10-7;488-55-1;Cyclohexanehexol;Inositol, meso-;cis-1,2,3,5-trans-4,6-Cyclohexanehexol;D-myo-Inositol;D-chiro Inositol;488-54-0;Bios I;Insitolum;Isoinositol;L-(-)-chiro-Inositol;(-)-Inositol;576-63-6;d-Inositol;L-Inositol;L-myo-Inositol;Inositol, allo-;Inositol, muco-;Inositol, i-;Inositol, scyllo-;Inositol (VAN);alloinositol;neoinositol;Hexahydroxycyclohexane;scyllo-Cyclohexanehexol;1D-myo-Inositol;1L-myo-Inositol;Inositol, cis-;Inositol, epi-;Inositol, neo-;epi-Cyclohexanehexol;(+)-Inositol;1,2,3,4,5,6-Cyclohexanehexol;(-)-chiro-Inositol;ELND005;Rat antispectacled eye factor;Levoinositol;CCRIS 6745;1,2,3,5-trans-4,6-Cyclohexanehexol, cis-;Mouse antialopecia factor;AZD 103;Chiro-inositol, (-)-;Inositol, myo;(1R,2R,3S,4R,5r,6S)-cyclohexane-1,2,3,4,5,6-hexaol;38876-99-2;MFCD00077932;(1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol;1,3,5/2,4,6-Hexahydroxycyclohexane;(1R,2R,3R,4R,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol;(1R,2R,3S,4S,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol;1-L-chiro-Inositol;Inositol, D-chiro-;ELND 005;(+)-Chiro-Inositol;CHEBI:17268;AI3-16111;NSC8101;1,3,5/2,4,6-cyclohexanehexol;1,2,3,5/4,6-Cyclohexanehexol;NSC 8101;NSC-8101;Chiro-inositol, (+)-;(1r,2R,3S,4r,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol;EINECS 201-781-2;(1R,2R,3R,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexaol;(1R,2R,3S,4S,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol;1,2,3,4,5,6-HEXAHYDROXY-CYCLOHEXANE;NSC-25142;NSC-55551;NSC404118;myo-Inositol;NSC 404118;NSC-404118;UNII-63GQX5QW03;UNII-8LQ63P85IC;UNII-9O6Y5O4P9W;UNII-R1Y9F3N15A;Inositol [Nonspecific isomer];UNII-4661D3JP8D;UNII-6R79WV4R10;UNII-M94176HJ2F;J101.890F;J101.891D;(1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol;63GQX5QW03;8LQ63P85IC;9O6Y5O4P9W;ELND-005;R1Y9F3N15A;(1R,2R,3R,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol;(1r,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol;(1s,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol;DTXSID7023146;UNII-1VS4X81277;CHEBI:10642;CHEBI:23927;CHEBI:27372;CHEBI:27987;AZD-103;4661D3JP8D;6R79WV4R10;M94176HJ2F;UNII-4L6452S749;UNII-587A93P465;Inositol (NF);Inositol (VAN8C;Inositol [NF];NSC45517;NSC55551;NSC55552;EINECS 207-681-5;EINECS 207-682-0;EINECS 209-000-7;EINECS 211-393-5;EINECS 211-394-0;EINECS 230-024-9;NSC 25142;NSC-55552;NSC-55558;1VS4X81277;NSC-103959;NSC-127230;INS;NCGC00159409-02;(1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexaol;(1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol;(1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol;4L6452S749;587A93P465;Inositol, myo- (8CI);MYO-INOSITOL-1,2,3,4,5,6-D6;1,3,4,5,6-Cyclohexanehexol;1,3,5/4,6-Cyclohexanehexol;DTXCID2065254;1,2,4/3,5,6-cyclohexanehexol;rel-(1r,2r,3r,4r,5r,6r)-Cyclohexane-1,2,3,4,5,6-hexaol;rel-(1R,2r,3S,4R,5s,6S)-Cyclohexane-1,2,3,4,5,6-hexaol;1,2,3,4,5,6-Cyclohexanehexol #;cis-1,2,3,4,5,6-cyclohexanehexol;CAS-87-89-8;cis-1,3,5-trans-4,6-Cyclohexanehexol;SMR000857145;SMR000857319;SMR000857320;Inositol NF 12;SR-05000001655;MFCD00065455;1,2,3,4,5,6-Hexahydroxycyclohexane;inositols;an inositol;Mio-inositol;Muscle sugar;inositol myo-;Myo- inositol;Inositol FCC;4irx;Inositol, chiro-;rac-chiro-inositol;Inosital (TN);CBU;EPIINOSITOL;(+)-Epi-Inositol;CHIRO-INOSITOLS;Epi-inositol, 98%;allo-Inositol, 97%;Inositol [USAN:NF];INOSITOL, MESO;Spectrum_001595;2os9;INOSITOL [INCI];INOSITOL [USAN];D-( )-chiro-Inositol;INOSITOL [FCC];INOSITOL [INN];orthorhombic myo-inositol;D-(+)-Chiro Inositol;DL-CHIRO-INOSITOL;INOSITOL [MI];INOSITOL (D);INOSITOL (L);INOSITOL [VANDF];Spectrum3_001053;Spectrum4_001193;Spectrum5_000961;myo-Inositol, >=99%;INOSITOL [MART.];bmse000102;bmse000103;bmse000113;bmse000901;bmse000922;D03SHD;D07CPO;D08DXZ;D0B1EY;D0Y4UQ;Epitope ID:144993;INOSITOL [USP-RS];INOSITOL [WHO-DD];scyllo-Inositol, >=98%;SCHEMBL5831;SCHEMBL5832;SCHEMBL5969;NCIOpen2_008191;BSPBio_002606;KBioGR_001885;KBioSS_002075;MLS001332377;MLS001332378;MLS001335965;MLS001335966;MLS001335967;MLS001335968;SCHEMBL187278;SCHEMBL187397;SCHEMBL187796;SCHEMBL188106;SCHEMBL188237;SCHEMBL491333;SCHEMBL959404;SCHEMBL959405;CHEMBL278373;CHEMBL468154;GTPL4495;GTPL4645;GTPL4648;GTPL4649;MEGxp0_001817;SCHEMBL1055883;SCHEMBL4748543;SCHEMBL6378921;SCHEMBL6468882;SCHEMBL6791918;CHEMBL1222251;CHEMBL1231671;CHEMBL1950780;CHEMBL3976780;SCHEMBL12371461;SCHEMBL12377889;SCHEMBL12411898;SCHEMBL12711208;SCHEMBL12735687;SCHEMBL13058696;SCHEMBL13114115;SCHEMBL13114116;SCHEMBL13114128;SCHEMBL13207905;SCHEMBL13580047;SCHEMBL14542470;SCHEMBL21388397;ACon1_002457;CHEBI:22357;CHEBI:23311;CHEBI:24848;CHEBI:25492;CHEBI:27374;D-(+)-chiro-Inositol, 95%;KBio2_002075;KBio2_004643;KBio2_007211;KBio3_001826;L-(-)-chiro-Inositol, 95%;AXD 103;DTXSID30110000;DTXSID50905091;myo-Inositol, p.a., 98.0%;1,2,3,4,5/6-cyclohexanehexol;1,2,3,4/5,6-cyclohexanehexol;1,2,3/4,5,6-cyclohexanehexol;1,2,4,5/3,6-cyclohexanehexol;DTXSID101028818;DTXSID101028820;DTXSID201028823;DTXSID301028826;DTXSID601028825;DTXSID901028824;HMS2091N13;HMS2230N03;HMS2235H05;HMS2235M23;HMS3369B06;HMS3369F20;HMS3373E05;Pharmakon1600-01500352;D-CHIRO-INOSITOL [USP-RS];D-CHIRO-INOSITOL [WHO-DD];1,2,3,4,5,6-Cyclohexanehexaol;BCP25172;HY-B1411;HY-N3021;MYO-INOSITOL [EP MONOGRAPH];NSC25142;NSC55558;D-myo-Inositol, Cell Culture Grade;Tox21_111642;Tox21_302035;CCG-36096;cis-Inositol, >=98.0% (TLC);MFCD00003863;MFCD00272608;MFCD00799555;MFCD00799556;MFCD01321249;NSC 55552;NSC 55558;NSC-45517;NSC103959;NSC127230;NSC757076;s4530;STL453612;epi-Inositol, >=98.0% (HPLC);1,2,3,4,5,6/0-cyclohexanetetrol;AKOS006240678;AKOS006332036;AKOS015895894;AKOS015912905;AKOS015912934;AKOS015960429;AKOS015960633;AKOS015994742;AKOS024318869;Tox21_111642_1;CS-4782;CS-W010757;CS-W017225;DB03106;DB13178;DB15350;HY-W010041;HY-W016509;HY-W021265;HY-W127726;J9.771C;KS-1284;KS-1420;LS-2350;NSC 103959;NSC 127230;NSC-757076;SB44732;SB45039;SB46764;SB46855;D-chiro-Inositol, >=98.0% (HPLC);NCGC00159409-03;NCGC00159409-04;NCGC00169828-01;NCGC00178580-01;NCGC00178580-03;NCGC00255362-01;AC-11070;AS-10616;AS-68396;AS-68424;cyclohexane-1R,2R,3S,4S,5R,6S-hexol;NCI60_041778;SY060836;myo-Inositol, purum, >=98.0% (HPLC);rac-chiro-1,2,3,4,5,6-cyclohexanehexol;SBI-0051369.P003;cis-1,2,4-trans-3,5,6-Cyclohexanehexol;HY-121962;J101.888D;J101.889B;J101.892B;myo-Inositol, for microbiology, >=99.0%;CS-0023004;CS-0039882;CS-0083766;CS-0185922;CS-0369552;FT-0627237;FT-0632208;FT-0632209;FT-0632730;FT-0652045;FT-0670351;FT-0670357;FT-0693444;FT-0693614;I0040;I0628;I0629;I0630;I0631;I0632;I0633;S6176;EN300-82941;myo-Inositol, BioUltra, >=99.5% (HPLC);myo-Inositol, SAJ special grade, >=99.0%;myo-Inositol, Vetec(TM) reagent grade, 99%;C00137;C06151;C06152;C06153;C19891;D08079;D78450;D91187;D91188;D91189;E78671;EN300-658805;F19572;I-6500;M01914;T72516;AB00051982_13;EN300-7361851;EN300-7411506;A834712;A836375;A866896;EN300-19631206;EN300-19632288;EN300-25914216;Q407997;Q743661;Q-201583;Q2838375;Q2974313;Q3011024;Q3023527;Q3205874;Q3331426;Q3347078;Q3589114;SR-05000001655-1;SR-05000001655-5;W-202861;W-202862;W-203081;W-203168;W-203392;1,2,4/3,5,6-Cyclohexane-1,2,3,4,5,6-hexol;7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5;1D7A27BF-6060-4FA9-AC46-3BD18DBA406E;220128F1-89BF-442D-AD6D-E6D1EA7BA625;Z1486007281;(1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexaol;(1R,2S,3r,4R,5S,6r)-cyclohexane-1,2,3,4,5,6-hexol;(1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol;(1R,2S,3s,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol;Inositol, United States Pharmacopeia (USP) Reference Standard;myo-Inositol, European Pharmacopoeia (EP) Reference Standard;(1R,2R,3S,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL;1,2,3,4,5,6-Cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #;1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta);Inositol, Pharmaceutical Secondary Standard;Certified Reference Material;1.ALPHA.,2.ALPHA.,3.BETA.,4.ALPHA.,5.BETA.,6.BETA.-CYCLOHEXANEHEXOL;173524-45-3;2H3;myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture

Chemical Property of Inositol

Chemical Property:

• Appearance/Colour: off-white powder
• Vapor Pressure: 0mmHg at 25°C
• Melting Point: 230 °C
• Refractive Index: 1.784
• Boiling Point: 291.326 °C at 760 mmHg
• PKA: 12.63±0.70(Predicted)
• Flash Point: 143.387 °C
• PSA: 121.38000
• Density: 2.038 g/cm³
• LogP: -3.83460
• Storage Temp.: Freezer
• Solubility.: Water
• Water Solubility.: 403.4g/L(11 oC)
• XLogP3: -3.7
• Hydrogen Bond Donor Count: 6
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 0
• Exact Mass: 180.06338810
• Heavy Atom Count: 12
• Complexity: 104

Purity/Quality:

98% ^*data from raw suppliers

1D-chiro-Inositol ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 24/25-36-26

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Chemical Classes: Biological Agents -> Monosaccharides and Derivatives
• Canonical SMILES: C1(C(C(C(C(C1O)O)O)O)O)O
• Recent ClinicalTrials: Inositol Treatment in Different Type of PCOS Phenotype
• Recent EU Clinical Trials: A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease.
• Uses: The inositols and their phosphates have been used in the development of metabolically stable insulin mediators, inhibitors, and modulators of important metabolic functions such as glycolysis. Inositols are stable to degradative enzymes in vivo because they lack a hydrolytically labile glycosidic linkage.

Technology Process of Inositol

There total 46 articles about Inositol which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 82.0%

(1S,3S,4S,6R,7S,8R,9R,10R)-3,4-diphenyl-2,5-dioxabicyclo-[4,4,0]decane-7,8,9,10-tetrol (215026-34-9) → D-chiro-inositol (488-54-0,488-55-1,488-58-4,488-59-5,551-72-4,576-63-6,643-10-7,643-12-9,6917-35-7,18685-70-6,38876-99-2,39907-99-8,40461-73-2,41546-32-1,41546-33-2,41546-34-3,41546-35-4,41546-36-5,87-89-8)

Guidance literature:

With hydrogenchloride; hydrogen; palladium dihydroxide; In ethanol; water; for 1h; under 775.7 Torr; Ambient temperature;

DOI:10.1039/a804072i

Reference yield: 77.0%

(1S,2R,3R,4S,5R,6S)-2,3-dihydroxy-4,5-di-O-isopropylidene-7-oxabicyclo<4.1.0>heptane (130669-73-7) → D-chiro-inositol (488-54-0,488-55-1,488-58-4,488-59-5,551-72-4,576-63-6,643-10-7,643-12-9,6917-35-7,18685-70-6,38876-99-2,39907-99-8,40461-73-2,41546-32-1,41546-33-2,41546-34-3,41546-35-4,41546-36-5,87-89-8)

Guidance literature:

With sodium benzoate; In water; for 83h; Heating;

DOI:10.1021/jo00060a061

Reference yield:

→ D-myo-inositol (87-89-8) + D-chiro-inositol (488-54-0,488-55-1,488-58-4,488-59-5,551-72-4,576-63-6,643-10-7,643-12-9,6917-35-7,18685-70-6,38876-99-2,39907-99-8,40461-73-2,41546-32-1,41546-33-2,41546-34-3,41546-35-4,41546-36-5,87-89-8)

Guidance literature:

With water; platinum; Hydrogenation;

upstream raw materials:

1L-chiro-inositol

D-chiro-inositol

myo-inositol

inositol peracetate

Downstream raw materials:

LACTIC ACID

tetrahydroxy-1,4-quinone

L-Lactic acid

DL-tartaric acid

Refernces

• 1、 -. "Optically active phenoxypropionic esters". . . Retrieved 2008/06/13.
• 2、 Mandel, Martin,Hudlicky, Tomas,Kwart, Lawrence D.,Whited, Gregg M.. "Unusual Oxidation of 1-Halo-1,3-dienes with Permanganate. Expedient Syntheses of (+)-D-chiro-3-Inosose and (+)-D-chiro-Inositol from Chlorobenzene". . p. 2331 - 2333. Retrieved 2007/10/02.